EGFR and rectal neoplasm: Another retrospective analysis of two Phase II Spanish trials described a reduced unconfirmed ORR (64% vs 80%, CI = 0.2–0.9) but similar PFS and OS in the rectal tumour group treated with anti-EGFR [21], which is different from our results to some degree.